strategy [menp]
CARDIOVASCULAR [bdsy]
assessment program [ocac]
Study [mnob]
PLAN [dsyn]
Integration [genf]
CARDIOVASCULAR [bdsy]
Assessment [hlca]
Study [mnob]
canagliflozin [carb, phsu]
CARDIOVASCULAR [bdsy]
Assessment [hlca]
study trials [resa]
Renal [bpoc]
Large [qnco]
CARDIOVASCULAR [bdsy]
Trial [resa]
canagliflozin [carb, phsu]
CARDIOVASCULAR [bdsy]
assessment program [ocac]
Study [mnob]
Complete [qlco]
canagliflozin [carb, phsu]
CARDIOVASCULAR [bdsy]
Assessment [hlca]
Study [mnob]
canagliflozin [carb, phsu]
CARDIOVASCULAR [bdsy]
Assessment [hlca]
Study [mnob]
Renal [bpoc]
Sodium-Glucose Transporter 2 Inhibitor [phsu]
Class [inpr]
Identified [qlco]
Question [inpr]
apparent [idcn]
Trial [resa]
Design [acty]
Series [qnco]
Modification [ftcn]
Make [ftcn]
Planned [ftcn]
Update [tmco]
Ensure [food]
CARDIOVASCULAR [bdsy]
assessment program [ocac]
Study [mnob]
Advance [medd]
Scientific [ocdi]
Knowledge [inpr]
patient care [hlca]
Specification [cnce]
strategy [menp]
Knowledge [inpr]
Trial [resa]
Design [acty]
Independent [idcn]
Scientific [ocdi]
Trial [resa]
Steering Committee [popg]
Detailed [qlco]
definition [idcn]
PLAN [dsyn]
External [spco]
Provided [acty]
Food and Drug Administration [hcro]
Efficient [qlco]
Robust [qlco]
utilization [ftcn]
CARDIOVASCULAR [bdsy]
assessment program [ocac]
Study [mnob]
Advance [medd]
Understanding [menp]
effects [qlco]
canagliflozin [carb, phsu]
Broad [spco]
Sodium-Glucose Transporter 2 Inhibitor [phsu]
Class [inpr]
Range [qnco]
Efficacy [qlco]
Safety [hcpp]
